Literature DB >> 21422162

Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships.

Michael T Klein1, Małgorzata Dukat, Richard A Glennon, Milt Teitler.   

Abstract

The 5-hydroxytryptamine (5-HT) 1E receptor is highly expressed in the human frontal cortex and hippocampus, and this distribution suggests the function of 5-HT(1E) receptors might be linked to memory. To test this hypothesis, behavioral experiments are needed. Because rats and mice lack a 5-HT(1E) receptor gene, knockout strategies cannot be used to elucidate this receptor's functions. Thus, selective pharmacological tools must be developed. The tryptamine-related agonist BRL54443 [5-hydroxy-3-(1-methylpiperidin-4-yl)-1H-indole] is one of the few agents that binds 5-HT(1E) receptors with high affinity and some selectively; unfortunately, it binds equally well to 5-HT(1F) receptors (K(i) ≈ 1 nM). The differences between tryptamine binding requirements of these two receptor populations have never been extensively explored; this must be done to guide the design of analogs with greater selectivity for 5-HT(1E) receptors versus 5-HT(1F) receptors. Previously, we determined the receptor binding affinities of a large series of tryptamine analogs at the 5-HT(1E) receptor; we now examine the affinities of this same series of compounds at 5-HT(1F) receptors. The affinities of these compounds at 5-HT(1E) and 5-HT(1F) receptors were found to be highly correlated (r = 0.81). All high-affinity compounds were full agonists at both receptor populations. We identified 5-N-butyryloxy-N,N-dimethyltryptamine as a novel 5-HT(1F) receptor agonist with >60-fold selectivity versus 5-HT(1E) receptors. There is significant overlap between 5-HT(1E) and 5-HT(1F) receptor orthosteric binding properties; thus, identification of 5-HT(1E)-selective orthosteric ligands will be difficult. The insights generated from this study will inform future drug development and molecular modeling studies for both 5-HT(1E) and 5-HT(1F) receptors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422162      PMCID: PMC3101003          DOI: 10.1124/jpet.111.179606

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Crystal structure of rhodopsin: A G protein-coupled receptor.

Authors:  K Palczewski; T Kumasaka; T Hori; C A Behnke; H Motoshima; B A Fox; I Le Trong; D C Teller; T Okada; R E Stenkamp; M Yamamoto; M Miyano
Journal:  Science       Date:  2000-08-04       Impact factor: 47.728

Review 2.  Serotonin receptors: their key role in drugs to treat schizophrenia.

Authors:  Herbert Y Meltzer; Zhu Li; Yasuhiro Kaneda; Junji Ichikawa
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-10       Impact factor: 5.067

Review 3.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.

Authors:  Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2002-03       Impact factor: 84.694

4.  Binding of tryptamine analogs at h5-HT1E receptors: a structure-affinity investigation.

Authors:  Małgorzata Dukat; Carol Smith; Katharine Herrick-Davis; Milt Teitler; Richard A Glennon
Journal:  Bioorg Med Chem       Date:  2004-05-15       Impact factor: 3.641

5.  Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 6.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

7.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

8.  N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.

Authors:  Y C Xu; K W Johnson; L A Phebus; M Cohen; D L Nelson; K Schenck; C D Walker; J E Fritz; S W Kaldor; M E LeTourneau; R E Murff; J M Zgombick; D O Calligaro; J E Audia; J M Schaus
Journal:  J Med Chem       Date:  2001-11-22       Impact factor: 7.446

Review 9.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

10.  Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.

Authors:  Fengju Bai; Tinggui Yin; Edward M Johnstone; Chen Su; Gabor Varga; Sheila P Little; David L Nelson
Journal:  Eur J Pharmacol       Date:  2004-01-26       Impact factor: 4.432

View more
  3 in total

1.  Distribution of 5-ht(1E) receptors in the mammalian brain and cerebral vasculature: an immunohistochemical and pharmacological study.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Structural insights into the lipid and ligand regulation of serotonin receptors.

Authors:  Peiyu Xu; Sijie Huang; Huibing Zhang; Chunyou Mao; X Edward Zhou; Xi Cheng; Icaro A Simon; Dan-Dan Shen; Hsin-Yung Yen; Carol V Robinson; Kasper Harpsøe; Bo Svensson; Jia Guo; Hualiang Jiang; David E Gloriam; Karsten Melcher; Yi Jiang; Yan Zhang; H Eric Xu
Journal:  Nature       Date:  2021-03-24       Impact factor: 49.962

3.  Molecular Cloning and Functional Characterization of Three 5-HT Receptor Genes (HTR1B, HTR1E, and HTR1F) in Chickens.

Authors:  Caiyun Sun; Yang Qiu; Qin Ren; Xiao Zhang; Baolong Cao; Yi Zou; Juan Li; Jiannan Zhang; Yajun Wang
Journal:  Genes (Basel)       Date:  2021-06-09       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.